http://www.unboundmedicine.com/medline/ebm/research/Augmentin_875Unbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.http://www.unboundmedicine.com/medline/ebm/record/19307171/full_citation/Influence_of_different_resistance_traits_on_the_competitive_growth_of_Haemophilus_influenzae_in_antibiotic_free_medium_and_selection_of_resistant_populations_by_different_{beta}_lactams:_an_in_vitro_pharmacodynamic_approach_González N, Aguilar L, Alou L, et al. 
Influence of different resistance traits on the competitive growth of Haemophilus influenzae in antibiotic-free medium and selection of resistant populations by different {beta}-lactams: an in vitro pharmacodynamic approach. [JOURNAL ARTICLE]
J Antimicrob Chemother 2009 Mar 22.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/18343748/full_citation/Efficacy_and_Safety_of_Azithromycin_1_g_Once_Daily_for_3_Days_in_the_Treatment_of_Community_Acquired_Pneumonia:_an_Open_Label_Randomised_Comparison_with_Amoxicillin_Clavulanate_875/125_mg_Twice_Daily_for_7_Days_Paris R, Confalonieri M, Dal Negro R, et al. 
Efficacy and Safety of Azithromycin 1 g Once Daily for 3 Days in the Treatment of Community-Acquired Pneumonia: an Open-Label Randomised Comparison with Amoxicillin-Clavulanate 875/125 mg Twice Daily for 7 Days. [Journal Article]
J Chemother 2008 Feb; 20(1):77-86.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/18162695/full_citation/Nocardia_nova_septic_arthritis_following_total_knee_replacement:_a_case_report_Nizam I, Kohan L, Kerr D 
Nocardia nova septic arthritis following total knee replacement: a case report. [Journal Article]
J Orthop Surg (Hong Kong) 2007 Dec; 15(3):390-2.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/17366027/full_citation/Efficacy_of_humanlike_Augmentin_SR__2000/125_mg__twice_daily_treatment_on_Haemophilus_influenzae_experimental_pneumonia_in_rabbits_Croisier D, Benoit M, Durand D, et al. 
Efficacy of humanlike Augmentin SR (2000/125 mg) twice daily treatment on Haemophilus influenzae experimental pneumonia in rabbits. [Journal Article]
Scand J Infect Dis 2007; 39(2):115-21.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/17341471/full_citation/Are_{beta}_lactam_breakpoints_adequate_to_define_non_susceptibility_for_all_Haemophilus_influenzae_resistance_phenotypes_from_a_pharmacodynamic_point_of_viewAlou L, Giménez MJ, Sevillano D, et al. 
Are {beta}-lactam breakpoints adequate to define non-susceptibility for all Haemophilus influenzae resistance phenotypes from a pharmacodynamic point of view? [JOURNAL ARTICLE]
J Antimicrob Chemother 2007 Mar 6.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/17223871/full_citation/Treatment_of_actinomycetoma_due_to_Nocardia_spp__with_amoxicillin_clavulanate_Bonifaz A, Flores P, Saúl A, et al. 
Treatment of actinomycetoma due to Nocardia spp. with amoxicillin-clavulanate. [Journal Article]
Br J Dermatol 2007 Feb; 156(2):308-11.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/17189093/full_citation/Human_serum_activity_of_telithromycin_azithromycin_and_amoxicillin/clavulanate_against_common_aerobic_and_anaerobic_respiratory_pathogens_Stein GE, Schooley S, Tyrrell KL, et al. 
Human serum activity of telithromycin, azithromycin and amoxicillin/clavulanate against common aerobic and anaerobic respiratory pathogens. [JOURNAL ARTICLE]
Int J Antimicrob Agents 2007 Jan; 29(1):39-43.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/16982294/full_citation/Levofloxacin_750_mg_QD_for_five_days_versus_amoxicillin/clavulanate_875_mg/125_mg_BID_for_ten_days_for_treatment_of_acute_bacterial_exacerbation_of_chronic_bronchitis:_A_post_hoc_analysis_of_data_from_severely_ill_patients_Grossman RF, Ambrusz ME, Fisher AC, et al. 
Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: A post hoc analysis of data from severely ill patients. [Journal Article]
Clin Ther 2006 Aug; 28(8):1175-80.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/16446376/full_citation/Efficacy_and_safety_of_twice_daily_pharmacokinetically_enhanced_amoxicillin/clavulanate__2000/125_mg__in_the_treatment_of_adults_with_community_acquired_pneumonia_in_a_country_with_a_high_prevalence_of_penicillin_resistant_Streptococcus_pneumoniae_Siquier B, Sánchez-Alvarez J, García-Mendez E, et al. 
Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae. [Journal Article, Randomized Controlled Trial]
J Antimicrob Chemother 2006 Mar; 57(3):536-45.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/15929954/full_citation/Patient_stratification_in_the_management_of_acute_bacterial_exacerbation_of_chronic_bronchitis:_the_role_of_levofloxacin_750_mg_Martinez FJ, Grossman RF, Zadeikis N, et al. 
Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
Eur Respir J 2005 Jun; 25(6):1001-10.
Abstract | Full Citation | Publisher Full Text | Find Related Articles